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Molecular characterization of post-thrombotic
syndrome
Lornie J. Phillips II, MD, and Rajabrata Sarkar, MD, PhD, San Francisco, Calif
The post-thrombotic syndrome represents a poorly understood and significant vascular health problem. This review
focuses on our current understanding of the pathogenesis of post-thrombotic syndrome. We emphasize the cellular and
molecular mechanisms that are responsible for the critical components of post-thrombotic syndrome. These include the
initiation of deep venous thrombosis, the pathogenesis of elevated venous pressure, and the factors responsible for
nonhealing of venous stasis ulcers. ( J Vasc Surg 2007;45:116A-122A.)A significant and common long-term complication af-
ter deep venous thrombosis (DVT) is the occurrence of
post-thrombotic syndrome, which consists of pain, edema,
and varying degrees of skin changes up to and including
chronic venous stasis ulcers. Estimates of the incidence of
post-thrombotic syndrome after DVT are variable and
range from 25% to 75%.1 Fortunately the severe manifesta-
tions of post-thrombotic syndrome are less common and
occur in 5% to 10% of patients after DVT. Post-thrombotic
syndrome is responsible for substantial disability, discom-
fort, and health care costs. In the United States, the annual
direct cost has been estimated to be at least $200 million.2
Because those affected are often of working age, the indi-
rect costs are also quite large, leading to 2 million workdays
lost annually in the United States.2 Thus post-thrombotic
syndrome, although not lethal, is a debilitating chronic
condition that deserves a clearer understanding to allow the
development of targeted therapy.
Several studies have examined the potential factors that
predict the onset and severity of post-thrombotic syndrome
after DVT. Recurrent DVT increases the risk of post-
thrombotic syndrome sixfold,3 and thus, the risks for de-
velopment of post-thrombotic syndrome are higher in pa-
tients with persistent prothrombotic risk factors such as
cancer or hypercoagulable states, most likely because of
recurrent or persistent DVT. A substantial fraction of DVT
patients do not go on to develop post-thrombotic syn-
drome, which suggests that alterations or derangements in
the process of thrombus resolution are critical in the patho-
genesis of post-thrombotic syndrome. This review de-
scribes our current knowledge regarding the pathogenesis
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116Aof post-thrombotic syndrome, with an emphasis on the
processes of DVT formation, thrombus resolution and the
alterations induced by venous hypertension that lead to
venous ulcers.
FACTORS PREDISPOSING TO POST-
THROMBOTIC SYNDROME
Venous thrombosis is a result of at least one of three
known predisposing factors (Virchow’s triad): hypercoagu-
lability, venous stasis, and endothelial damage. The clinical
risk factors for DVT development include hypercoagulable
states (both familial and acquired), trauma, pregnancy,
lower extremity fractures, malignancy, and surgery involv-
ing the lower extremities, pelvis, or abdomen.
Two basic pathologic mechanisms are involved in the
initiation of DVT. In patients without direct trauma or
manipulation of the veins, stasis and hypercoagulability
induce thrombosis, usually starting in the calf veins. The
process often begins on the upper aspect of the valve cusps,
where localized stasis and turbulence create a nidus for
thrombus initiation. The secondmechanism involves direct
trauma, manipulation, or compression of a segment of vein
causing thrombus formation at the site of endothelial dam-
age. Common clinical examples of this mechanism include
DVT secondary to vein compression from popliteal or
femoral aneurysms, thrombosis of iliac veins manipulated
during pelvic surgery, and thrombosis in vein segments
adjacent to displaced fractures.
Once the thrombus forms in the vein, endogenous lysis
results in recanalization and reabsorption of the mass.
Extension of the thrombus can occur simultaneously with
thrombolysis, and the overall progression of the initial
DVT towards propagation or resolution depends on the
balance between these two processes. If conditions favoring
thrombosis are present in adjacent venous segments, then
extension or propagation of the thrombus is likely. This is
illustrated clinically by the higher incidence of persistent
DVT in patients with ongoing hypercoagulable conditions.
Concurrently, the resultant venous obstruction induces
enlargement of collateral veins around the region of throm-
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the venous valves and lead to venous reflux.
ROLE OF CHEMOKINES AND GROWTH
FACTORS
The initial thrombotic event involves the generation of
a cross-linked fibrin matrix containing platelets and mini-
mal inflammatory cells. The activated platelets initially re-
lease angiostatic chemokines such as platelet factor-4, but
as the thrombusmatures and becomesmore cellular (24 to 72
hours), the chemokines released are neutrophil andmonocyte
chemoattractants such as interleukin-8 (IL-8), which is a
proinflammatory, proangiogenic chemokine known to attract
polymorphonuclear neutrophils (PMNs).4,5 Intravenous ad-
ministration of IL-8 accelerated thrombus resolution as
measured by thrombus weight in a rat model of stasis
induced venous thrombosis.6 The peak effect of IL-8 was
noted upon administration between day 4 and day 8, when
the cellular composition of the resolving thrombus begins
to change from neutrophils, the predominant early cell
type, to monocytes.
A variety of growth factors have been found to be active
within the resolving thrombus. Vascular endothelial
growth factor (VEGF) increases after day 1 within the
thrombus and peaks between day 14 and 21 in a flow
constriction model of thrombosis.7 However, basic fibro-
blast growth factor (bFGF) increases in the thrombus in a
linear fashion over time, with a 300-fold difference in
expression found between day 1 and 28. No change in
serum or vein wall concentration was noted for either
VEGF or bFGF. VEGF was expressed by endothelium and
the monocyte infiltrate within the thrombus, although the
endothelial expressionmay be constitutive and unrelated to
thrombus resolution. Mononuclear cells and spindle
shaped cells within the thrombus were found to express
bFGF.
VEGF and bFGF are regulators of angiogenesis and
may regulate the formation of the neovascular channels that
connect with both lumen and vasa vasorum. A later study8
used plasmid-mediated gene transfer of VEGF to attempt
to accelerate thrombus resolution. There was a 48% reduc-
tion in mean thrombus area and 31% increase in the per-
centage of thrombus area that was recanalized. This sug-
gests that the recanalization process is positively influenced
by cytokines and the cells that they recruit, rather than
being a passive mechanical retraction of the fibrin clot
during maturation.
The possibility that angiogenic chemokines and growth
factors present in DVT could be used to accelerate throm-
bus resolution has spurred several additional studies. Ad-
ministration of IL-8, monocyte chemotactic protein-1
(MCP-1), and VEGFwas beneficial in experimental throm-
bus resolution.8 More mixed results were noted with injec-
tion of angiogenic cytokines such as the angiostatic chemo-
kine interferon-inducible protein (IP10), bFGF, and
epithelial neutrophil–activating protein (ENA-78) directly
into experimental DVT.9 At 8 days, control and IP10-
treated rats had similar number of intrathrombus channels,and animals treated with ENA-78 and bFGF showed a
small increase in number of channels, but only bFGF
induced an actual increase in blood flow within the resolv-
ing thrombus as measured by Doppler flow probes. Be-
cause these experiments involved complete surgical ligation
of the rodent infrarenal vena cava, it is not clear what the
physiologic significance of intrathrombus flow is. This
model has a different pattern of recanalization and throm-
bus remodeling than clinical DVT and flow restriction
models of thrombus resolution.
Channel formation within the thrombus, which has
also been described as neovascularization, was originally
thought to be secondary to clot retraction. It is now pos-
tulated to be an active and directed component of throm-
bus resolution. It has been shown that the cells lining the
vascular channels express the endothelial marker von Wil-
lebrand factor10 and the potent angiogenic chemokine
IL-8. Exogenous IL-8 increased early neovascularization
and promoted leukocyte influx11 during thrombus resolu-
tion after infrarenal vena caval ligation. IL-8 administration
also increased intrathrombus PMN on day 4, monocyte
infiltration on day 8, and fibroblasts within the thrombus at
all time points. Total intrathrombus channel volume, as de-
termined by a fluorescent high-molecular-weight marker, was
also increased in animals treated with IL-8. It has been pro-
posed that intrathrombotic channels play a critical role by
allowing leukocyte influx and subsequent fibrinolytic protease
release.10
Plasmin lyses clot by breaking down fibrinogen and
fibrin within the clot. The major direct activator is tissue
plasminogen activator (tPA), a molecule synthesized as a
single-chain molecule in endothelial cells. It promotes con-
version of plasminogen to plasmin, in presence of fibrin.
The resulting complex can then convert additional plasmin-
ogen to plasmin.12 Elastase is one of the primary proteases
released by PMNs and acts with tPA to lyse thrombus.13
Interestingly, studies of the urokinase-type plasminogen
activator (uPA) and tPA knockout mice, demonstrate that
the uPA gene, but not the tPA gene, is critical to thrombus
resolution.14
ROLE OF CELL TYPES
What is the role of the various cell types in the resolving
thrombus? Is it analogous to wound healing? The primary
focus in the literature has been on the role of neutrophils
and monocytes on thrombus resolution. One experiment
that investigated the role of the neutrophils used a neutro-
penic rat model15 on the basis of the observation that
multiple episodes of neutropenia were a potential clinical
risk factor for a venous thromboembolic event.16 The rats
were treated with antineutrophil serum and then under-
went vein ligation to generate experimental DVT.15
Intrathrombus monocyte numbers remained un-
changed, but the rats were neutropenic throughout the
experimental time points. The thrombus in these rats was
larger by both weight/length ratio and in vivo area. The
thrombi of neutropenic rats were also increasingly fibrotic,
with a 3.3-fold increase in collagen noted. Although colla-
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ment, it is plausible that the lack of collagen turnover was
due to decreases in neutrophil-derived matrix metallopro-
teinases (MMPs) and elastase.
Most of the chemokines tested were similar between
groups, but keratinocyte cytokine was elevated by 20-fold
in the neutropenic group. Macrophage inflammatory pro-
tein 1 and monocyte chemoattractant protein-1 were
lower in neutropenic animals, indicating a role for neutro-
phils in affecting the cytokine pattern during thrombus
resolution.
Monocytes are predominant in the venous thrombus at
day 8, where they help orchestrate resolution of the throm-
bus by fibrinolytic, chemotactic, and angiogenic mecha-
nisms. Monocytes can degrade fibrin in the absence of
plasmin.17 Monocytes that infiltrate experimental thrombi
express plasminogen activators.18 When exogenous macro-
phages generated by peritoneal lavage were injected into
experimentally induced thrombi, thrombus size decreased
fivefold and recanalization increased more than fourfold.19
MCP-1 is produced by fibroblasts, smooth muscle,
endothelium, and monocytes and serves to attract and
activate monocytes and basophils. The vein wall demon-
strates increased amounts of MCP-1 in experimental DVT,
which plays a role in thrombus and vein wall monocyte
infiltration.20 Endogenous MCP-1 expression increases
from 1 to 7 days after DVT formation and remains elevated
for 14 days. Injection of exogenous MCP-1 into experi-
mentally produced thrombi resulted in increased thrombus
organization, decreased cross-sectional area, and lower
thrombus weights. This treatment, surprisingly, did not
affect numbers of monocytes within the thrombus, but they
were significantly increased in the vein wall. Themonocytes
have been shown previously to move into the thrombus
after vein wall infiltration, rather than direct deposition
from flowing blood into the thrombus.20 Mice deficient in
the cysteine-cysteine chemokine receptor 2 (CCR2), which
mediates chemotactic movement of monocytes in response
to MCP-1, had thrombi with significantly lower macro-
phage content. Thrombus resolution was also impaired in
these mice.19
MECHANISMS FOR SUBSEQUENT POST-
THROMBOTIC SYNDROME
If the DVT completely resolves, what leads to subse-
quent post-thrombotic syndrome? Numerous mechanisms
have been postulated, and the increased fibrotic nature of
the vein wall is thought to be one cause (Fig 1). DVT
induces a paracrine-like scarring process in the adjacent vein
wall and subsequent fibrosis.21 In a mouse model of DVT,
the presence of thrombus leads to an increase in total vein
wall collagen over time, peaking at 12 days after thrombus
formation in the model. The authors also demonstrated a
corresponding increase in procollagen I and III messenger
RNA (mRNA).21
The fibrosis contributes to valve failure. This, in turn,
appears to promote venous hypertension, a critical factor in
the development and persistence of chronic venous ulcersin humans.22 Prolonged approximation of the delicate
venous valve leaflet against the vein wall or entrapment
within the thrombus during the intense inflammatory pro-
cess leads to leaflet destruction. Loss of valve leaflets results
in deep venous reflux, which allows postural changes in the
static venous pressure to be directly transmitted to the
lower leg. The elevated venous pressure in the lower aspect
of the limb leads to dysfunction of the microcirculation,
which can then lead to reflux, varicose veins, and finally,
ulcers. Inflammatory changes have been noted in the valve
leaflets, with infiltration by monocytes and macrophages
greatest in the valve sinus and proximal venous wall.23
The changes in collagen compositionmay be due to the
localized action of leukocytes. Peripheral blood samples of
patients with chronic venous insufficiency have shown ac-
tivated leukocytes accumulate in the lower extremity in
patients with venous hypertension.24,25 Leukocytes are
known to express multiple matrix metalloproteinases
(MMPs), which play a significant role in collagen degrada-
tion. The MMPs are a family of soluble and membrane-
bound zinc-dependent endopeptidases that participate in
tissue remodeling during morphogenesis, tumor progres-
sion, cell migration, angiogenesis, and wound healing.
Released in zymogen form, they can be extracellularly
activated by cleavage of the aminoterminal propeptide.
MMP-8 and MMP-9 have been shown to be secreted by
neutrophils and macrophages, and interstitial macrophages
have been shown to express MMP-1 and MMP-3. The
macrophages are thought to use these proteinases to de-
grade the extracellular matrix and to assist digestion of
stromal collagen fibers.
The hypothesis of valve failure as a possible cause of
MMP activation, leading to perpetuation of an inflamma-
tory cascade, has been tested (Fig 2). When venous blood
pressure was elevated experimentally by creation of a fem-
oral arteriovenous fistula in rats, venous reflux increased
fivefold during a period of 6 weeks.26 The valves were
dilated and the vein walls appeared to weaken. The activity
of MMP-2 in the vein was increased, with a peak at 7 days,
and remained elevated at 42 days. MMP-9 activity was also
significantly above controls at day 7, but this effect did not
Fig 1. A resolving thrombus formed by vein constriction in the
mouse, 7 days postprocedure.last through the time course.
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ULCERS
What are the mechanisms by which elevated venous
pressure induces nonhealing skin ulcers? Ambulatory ve-
nous hypertension is caused by superficial and deep venous
incompetence, and subsequent alteration of the skin micro-
circulation is thought to lead to ulceration.27 Capillaries
become dilated and tortuous as they respond to increased
hydrostatic pressure. They then begin to leak plasma, pro-
teins, and erythrocytes. Chronic leakage of fibrinogen leads
to formation of extravascular cross-linked fibrin around the
capillaries, noted histologically as fibrin cuffs. This pericap-
illary protein acts as a barrier to decrease oxygen diffusion
from the capillaries and thus contributes to tissue hypoxia,
despite adequate arterial supply. The blood flow in the
dysfunctional capillaries is hampered to the point where
some become occluded (Fig 3).
The findings of increased MMP activity and their po-
tential role is supported in human subjects by the finding of
an imbalance in between type I collagen and type III
collagen in the proximal segments of varicose veins.28 That
Fig 2. The connection between deep venous thrombosis and the
post-thrombotic syndrome.
Fig 3. The path from local increased venous hydrostatic pressure
leads to ulceration and failure to heal. MMP, Matrix metallopro-
teinase.same group found that type III collagen was degradedextracellularly in cultures of smoothmuscle cells taken from
varicose veins compared with controls, and that the pro-
duction of type III collagen was partially restored in the
presence of a synthetic MMP inhibitor. These studies indi-
cate that varicose veins have particular differences in their
protease expression profile that may play a role in the
pathogenesis of venous insufficiency.
MMPs have been implicated in the excessive extracel-
lular matrix degradation within the chronic venous ulcers
that may contribute to the failure to heal. Venous ulcer
patients have been categorized into healing and nonhealing
groups.29 Nonhealing ulcers were defined as 20% reduc-
tion in ulcer surface area at 8 weeks. There was a trend
(although not statistically significant) toward higher levels
of MMP-2 in the nonhealing ulcers, with a concomitant
decrease in tissue inhibitor of metalloproteinase-2 (TIMP-
2). Other groups30,31 have seen MMP activity in both
lipodermatosclerosis and frank ulceration, so it is likely that
this result was more the effect of a small sample size.
TIMPs are believed to regulate proteolytic activity of
MMPs by binding to them. Decrease of TIMP can lead to
imbalance in TIMP/MMP ratio, with a net excess of acti-
vated MMPs within the chronic wound. There was a cor-
relation (r  0.94) noted between higher MMP-2 and
lower TIMP-2 in the nonhealing group, suggesting an
increase in proteolytic activity was due to the balance
between these two factors.
Platelet derived growth factor-AA (PDGF-AA) was
also found to be increased in the healing group of this
study.29 This growth factor stimulates other growth factors
and production of matrix components collagen and hyal-
uronic acid. It is also known to stimulate smooth muscle
cell migration, angiogenesis, and collagenase production.
Is impaired healing associated with decrease in PDGF?
PDGF AA is up-regulated in capillaries and fibroblasts of
acute and chronic wounds, but not in nonhealing dermal
wounds or normal skin.32 PDGF has been found to stim-
ulate MMP production in fibroblasts.33
Extracellular matrix metalloproteinase inducer
(EMMPRIN) is another potentially important protein
noted to have higher expression perivascularly in biopsies of
venous leg ulcers than biopsies of the skin of healthy
controls.30 EMMPRIN is a membrane-bound glycopro-
tein produced by normal keratinocytes.34 It has been
shown to stimulate synthesis of MMP-1, MMP-2, and
MMP-3 de novo in cultures of human fibroblasts.35
Expression of EMMPRIN is elevated in the dermal
structures of chronic ulcers along with membrane-type
MMP 1 (MT1-MMP, or MMP-14) and MT2-MMP
(MMP-15).30 MMP-2 and EMMPRIN were the only ones
of this group of enzymes to be elevated perivascularly.
MMP-1 andMMP-2 are secreted as zymogens and are then
activated by proteolytic cleavage, mostly by serine proteases
such as plasmin. The activity of these proteins then results
in enhanced turnover of the extracellular matrix. Plasmin
and the plasminogen-activating cascade components were
not found in the dermal structures,36 and therefore, it is
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EMMPRIN.
Plasminogen activation in both venous ulcers and lipo-
dermatosclerosis is enhanced by uPA and its receptor.31
Analysis of human ulcer biopsies showed mRNA and pro-
tein levels of uPA and its receptor to be elevated in venous
ulcers. Immunohistochemical staining of venous leg ulcers
showed that the plasminogen activator is enhanced perivas-
cularly. Tissue-type plasminogen activator was not ele-
vated. Elevated plasminogen activation implies that main-
tenance of proteolytic activity is an important component
of the pathophysiology of venous leg ulcers, and this may
be a response to the well-described presence of perivascular
fibrin cuffs, depositions of fibrin and collagen around the
microvasculature.
Lipodermatosclerosis is a precursor state to venous
ulceration characterized primarily by skin induration and
scleroderma-like hardening. Histologic analysis demon-
strates the loss of cellular components and formation of
fibrous scar tissue of the reticular dermis composed of
collagen bundles and degraded elastic fibers. In addition,
fibrin cuffs, which contain I and III collagen and fibronec-
tin in addition to fibrin, are found around the dermal
capillary vessels.37 Elevated MMP-1, MMP-2, and TIMP-1
gene expression (but not MMP-9 or TIMP-2) has been
identified in skin biopsy specimens of patients with lipoder-
matosclerosis.31 They were able to determine increased
collagenolytic activity as well. The MMP-1 protein was
found diffusely in epidermis and dermis, whereas MMP-2
was centered perivascularly and around collagen bundles.
MMP-2 cleaves collagen I and III, as well as elastin, type IV
collagen, fibronectin, and laminin.
It is tempting to speculate that the increased extracel-
lular matrix turnover found in lipodermatosclerosis might
be a result of increasedMMP-2 activity. TIMPs control the
activity of MMP-2 by forming one-to-one complexes with
MMP-2. TIMP-2 is more than sevenfold effective than
TIMP-1.38 No concomitant increase in TIMP-2 was
found, so the activity of MMP-2 is likely enhanced because
of decreased inhibition in addition to increased expression.
Granulocyte-macrophage colony stimulating factor
(GM-CSF) is a potent cytokine that has been used to treat
chronic venous skin ulcers.39 Multiple studies that used
GM-CSF noted success for chronic wounds, but it does not
enhance repair of acute wounds in healthy individuals.40
The possible indirect actions of GM-CSF on healing of
chronic ulcers have been investigated.41 After the wounds
of human subjects were injected with GM-CSF, VEGF
expression within the ulcer in multiple cell types (mainly
macrophages) was increased compared with preinjection
levels in the same subject. Blood vessel density was also
increased in these specimens. These authors postulated that
the mechanism of action was to increase vascularization by
induction of angiogenic factors released by hematopoietic
cells.
VEGF is known to be important in angiogenesis as a
mitogen and chemoattractant for endothelial cells.42 Se-
creted VEGF is degraded by proteolytic activity of thewound exudates of chronic venous ulcers.43 It is possible
that the effect of GM-CSF on venous ulcers is to increase
expression of VEGF, leading to improved angiogenesis and
wound resolution. Culturing PMA-differentiated mono-
cytes indirectly tested one aspect of this hypothesis, and a
two-fold increase in VEGF expression was observed 12
hours after treatment with GM-CSF.
Transforming growth factor-1 (TGF-1) is a cytokine
associated with both tissue remodeling and regulation of
MMP activity.44,45 Previous studies have shown a correla-
tion between TGF-1 level in venous ulcer and disease
severity.46 Because TGF-1 is known to transcriptionally
regulate MMP-1, MMP-2, and MMP-9, Siato et al47 hy-
pothesized that the increased activity of TGF would be
associated with differences in mRNA and protein levels of
these MMPs. Patients were grouped by CEAP class, and
the control group consisted of patients with arterial disease
but no clinical evidence of chronic venous insufficiency.
Their analysis of lower extremity venous ulcer biopsy spec-
imens showed that MMP-1 mRNA was decreased and
TIMP-1 mRNAwas increased. However, the protein levels
of MMP-1 and TIMP-1 were no different from controls.
One way to interpret this dissociation is the possibility that
post-transcriptional modification is also an important reg-
ulatory mechanism of synthesis and activity of these two
proteins.
This is one of several groups of authors who have seen
increased active and latent forms of MMP-2 in the chronic
venous wound.48-50 Increased MMP-9 activity was not
observed, reflecting previous results.31 TGF-1 is proposed
to suppress MMP gene expression by binding to an inhib-
itory element of the MMP promoter. MMP-2 lacks this
element, which would explain its continued increased ex-
pression despite increased TGF-1 levels.
Another intriguing action of MMPs that may affect
healing of chronic venous ulcers is the inhibition of angio-
genesis. Although MMP proteins are generally associated
with angiogenesis because they are involved in endothelial
cell and vascular smooth muscle cell migration, MMPs are
also responsible for generation of angiostatic (antiangio-
genic) molecules such as angiostatin by the cleavage of
plasminogen to generate an NH3 terminal fragment that
inhibits endothelial cell proliferation. MMPs can also pro-
teolytically generate endostatin, a proteolytic fragment of
collagen XVIII,51-53 which also has antiangiogenic activity.
Granulation tissue is an essential feature of resolution of
wounds and is dependent on the development of new
capillaries from the wound edge. Chronic ulcers typically
do not form granulation tissue. Could it be an increased
angiostatic response that is mediating this observation?
Ulrich et al54 used an in vitro model of angiogenesis to
investigate this question. A coculture of human umbilical
vein endothelial cells and diploid fibroblasts was treated
with the wound exudates of patients with chronic venous
ulcers and acute wound fluid from skin grafts for partial
thickness burns. The length of tubules that formed after
treatment with chronic wound exudates was almost one
third the length of those that were treated with the exu-
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the length of those treated with suramin, a known angio-
genesis inhibitor. However, when a synthetic MMP-2/
MMP-9 inhibitor was added to the chronic wound fluid,
the tubule length significantly increased. This study did not
definitively explain the role of MMP-2 or MMP-9 in an-
giostasis, but it did demonstrate that the antiangiogenic
milieu in chronic wound fluid is MMP-dependent, and this
may contribute to the chronic nonhealing state character-
istic of venous ulcers.
Examination of the growth potential of fibroblasts
taken from nonhealing venous ulcers reveals another po-
tential contributing factor to ulcer persistence. The reduc-
tion in proliferative capacity of differentiated mammalian
cells after a certain number of proliferative cycles is known
as cellular senescence. Decreased growth in cell culture and
other characteristics of cellular senescence have been noted
in fibroblasts isolated from nonhealing venous ulcers, but
not from thigh biopsy specimens of the same patients.55
This suggests that the prolonged nonhealing noted in
chronic venous stasis ulcers may be due to exhaustion of the
proliferative capacity of skin fibroblasts. It remains to be
determined if molecular therapy targeting the cellular
mechanisms responsible for senescence, such as telomerase
activity, will be applicable for this most severe complication
of post-thrombotic syndrome.
CONCLUSION
The post-thrombotic syndrome is a chronic and debil-
itating complication of DVT. The thrombus can create
elevated venous pressure by mechanical obstruction. Even
when the thrombus is resolved, the resultant fibrosis can
cause valve damage, which leads to reflux and subsequent
localized venous hypertension. The vein walls become di-
lated and valve leaflets fail to approximate, only furthering
the venous hypertension. Capillary leak is a dire result of
this elevated hydrostatic pressure that induces edema and
subsequent chronic inflammation. Venous stasis within the
microcirculation accumulates leukocytes, which, in addi-
tion to erythrocytes, fibrinogen, and other macromole-
cules, leak out into the interstitium and further contribute
to persistent localized inflammation.
Enhanced extracellular matrix turnover by increased
MMP activity can lead to fibrin and collagen deposition
around the dermal capillaries and the generation of fibrin
cuffs that impair oxygenation and nutrient perfusion. Loss
of epidermal integrity then follows, and the resultant ulcer
demonstrates increased proliferation of the fibroblasts,
whichmay become senescent. In addition, the imbalance of
MMP/TIMP within the wound impairs angiogenesis and
inhibits granulation tissue formation. The synergy between
these complex relationships leads to a dermal environment
that is unable to heal and allows the persistence of the
venous ulcer, which is the most serious manifestation of the
post-thrombotic syndrome.REFERENCES
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